AYLAライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (19 1月 2023 @ 05:56):

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers...

Stats
本日の出来高	137 793
平均出来高	50 544.00
時価総額	0.00
EPS	$0 ( 2023-03-27 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0760 (15.09%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-18	Martell Bridget A	Buy	0
2023-10-18	Orbach Pini	Buy	0
2023-10-18	Golan Roy	Buy	0
2023-01-19	Amoon Growth Fund Limited Partnership	Sell	2 991 473	Common Stock
2023-01-19	Sidransky David	Sell	12 500	Stock Option (right to buy)

INSIDER POWER
-97.76
Last 84 transactions
Buy: 4 327 382 \| Sell: 8 482 924

ボリューム相関

長: 0.26 (neutral)

短: -0.81 (strong negative)

Signal:(50.563) Neutral

Ayala Pharmaceuticals Inc 相関

10 最も正の相関
SPCB	0.933
MERC	0.928
ATER	0.927
YELL	0.923
STAF	0.922
CSSE	0.922
SISI	0.922
VCSA	0.921
ASPS	0.916
PASG	0.915

10 最も負の相関
SCPL	-0.914
CBAY	-0.912
HEES	-0.91
JMPNZ	-0.907
TWCB	-0.906
MSDA	-0.901
THCP	-0.901
ZING	-0.9
ROC	-0.899
AEAE	-0.898

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Ayala Pharmaceuticals Inc 相関 - 通貨/商品

0.49
( neutral )

-0.43
( neutral )

0.00
( neutral )

0.15
( neutral )

0.48
( neutral )

-0.57
( weak negative )

Ayala Pharmaceuticals Inc 財務諸表

Annual	2022
収益:	$692 000
総利益:	$90 000.00 (13.01 %)
EPS:	$-2.46

FY	2022
収益:	$692 000
総利益:	$90 000.00 (13.01 %)
EPS:	$-2.46

FY	2021
収益:	$0.00
総利益:	$-3.51M (0.00 %)
EPS:	$-4.69

FY	2020
収益:	$3.71M
総利益:	$0.00 (0.00 %)
EPS:	$-3.06

Financial Reports:

No articles found.

Ayala Pharmaceuticals Inc

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.